Loading
Solid Biosciences Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Mar 2025.
Solid Biosciences Inc.: what insiders have been doing
Solid Biosciences Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). 8 insiders have disclosed 35 filings since 18 October 2025.
The flow runs one way only: 9 sales worth €712k, from 7 insiders, and no purchase. One trade stands out by size: a sale of €267k from Cumbo Alexander, disclosed on 6 February 2026.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 35 filings, this issuer sits above that mark. The full history, which starts in 2022, counts 7 purchases against 13 sales.
Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
97
Thresholds
n/a
Buy Volume
€47M
7 ops. · all time
Sell Volume
€756,292
13 ops. · all time
Who traded when
BuySaleGabriel Brooks2 sales
Ilan Ganot2 sales
Adage Capital Management, L.P.1 buy
Alexander Cumbo1 sale
Bain Capital Life Sciences Investors, LLC1 buy
Clare Kahn1 buy
+5 other insiders
Since the insiders bought
- +47.0%Entry US$5.09 · Close at T+365 US$7.48
- +5.2%Entry US$5.58 · Close at T+365 US$5.87
- +5.2%Entry US$5.58 · Close at T+365 US$5.87
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Solid Biosciences Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$18.62.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,978 of 24,148 companies
21.1
score / 100
Value8
Quality34
FCF yld-26%
Earn yld-28%
EV/EBITDA·
ROE-66%
Gross mgn43%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$5.82
Analyst consensus
13 analystsStrong buy
US$11.00Target US$18.62(+220%)US$26.00
Income statement
RevenueUS$59.3M
Gross profitUS$25.3M43% margin
EBITDA-US$177.6M-300% margin
Net income-US$174.3M0.0% margin
Valuation
PER (forward)-3.4x
P/Book1.6x
Beta2.47
Balance sheet & cash
Market capUS$624.1M
Total debtUS$21.2M
Free Cash Flow-US$157.4M
Debt / Equity5%
Profitability & ownership
ROE-65.5%
ROA-36.4%
% insiders0.7%
% institutions107.6%
Last declaration on 6 October 2026
Declarations97 total
3,440 sharesCommon StockSEC:0001193125-26-415649:0
3,440 sharesCommon StockSEC:0001193125-26-297456:0
3,441 sharesCommon StockSEC:0001193125-26-140056:0
30,031 sharesCommon StockSEC:0001193125-26-057878:0
8,125 sharesCommon StockSEC:0001193125-26-057872:0
4,861 sharesCommon StockSEC:0001193125-26-057868:0
7,187 sharesCommon StockSEC:0001193125-26-057865:0
14,687 sharesCommon StockSEC:0001193125-26-057863:0
10,937 sharesCommon StockSEC:0001193125-26-057859:0
12,348 shares@ US$6.4419100.0% of flowCommon StockSEC:0001193125-26-041507:0
48,913 shares@ US$6.4419100.0% of flowCommon StockSEC:0001193125-26-041519:0
7,205 shares@ US$6.441976.4% of flowCommon StockSEC:0001193125-26-041516:0
12,616 shares@ US$6.441968.0% of flowCommon StockSEC:0001193125-26-041511:0
10,905 shares@ US$6.4419100.0% of flowCommon StockSEC:0001193125-26-041506:0
18,894 shares@ US$6.4419100.0% of flowCommon StockSEC:0001193125-26-041523:0
79,341 sharesCommon StockSEC:0001193125-26-034080:0
54,925 sharesCommon StockSEC:0001193125-26-034076:0
15,000 sharesCommon StockSEC:0001193125-26-034072:0
169,401 sharesCommon StockSEC:0001193125-26-034087:0
54,925 sharesCommon StockSEC:0001193125-26-034085:0
58,847 sharesCommon StockSEC:0001193125-26-034083:0
389 sharesCommon StockSEC:0001193125-26-031765:0
25 of 97 declarations
About Solid Biosciences Inc.
Solid Biosciences Inc. is a biopharmaceutical company focused on developing treatments for rare genetic diseases, particularly Duchenne muscular dystrophy. The company is listed on NASDAQ under the symbol SLDB.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
